Alisha Leigh Johnston, DPM | |
1001 7th Street Ne, Devils Lake, ND 58301-1100 | |
(701) 662-2157 | |
(701) 662-4116 |
Full Name | Alisha Leigh Johnston |
---|---|
Gender | Female |
Speciality | Podiatrist |
Location | 1001 7th Street Ne, Devils Lake, North Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1952601312 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213E00000X | Podiatrist | 71 (North Dakota) | Primary |
213ES0103X | Podiatrist - Foot & Ankle Surgery | 71 (North Dakota) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Alisha Leigh Johnston, DPM 2401 Demers Ave, Grand Forks, ND 58201-4183 Ph: (701) 780-4085 | Alisha Leigh Johnston, DPM 1001 7th Street Ne, Devils Lake, ND 58301-1100 Ph: (701) 662-2157 |
News Archive
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services announced a number of professional educational opportunities that will focus on ATS Medical products at the upcoming European Association for Cardio-Thoracic Surgeons (EACTS) meeting.
Coronary artery disease (CAD) is one of the world's most prevalent and silent killers. Positron emission tomography (PET), which images miniscule abnormalities in cellular metabolism, can tip off clinicians about cardiac disasters waiting to happen- including sudden death from a heart attack-better than standard angiography, researchers revealed at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
A major new study has identified 2085 excess deaths in England and Wales due to heart disease and stroke during the peak of the COVID-19 pandemic. On average, that is 17 deaths each day over four months that probably could have been prevented.
DebMed today announced a three-year agreement with Cooley Dickinson Hospital for the use of its Group Monitoring System, the only electronic hand hygiene monitoring system that complies with the World Health Organization's Five Moments for Hand Hygiene and Centers for Disease Control and Prevention guidelines.
› Verified 5 days ago